Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Are Checkpoint Inhibitors Appropriate for Pediatric Brain Tumors Selected by Biomarkers?

  • By

  • Yaxel Levin-Carrion

  • Jayant Bhasin

  • Kevin Titkov

  • Sraavya Anne

  • Arman Sawhney

  • Caryn J. Ha

  • Ibraheem Sharaf

  • Marvens Jean

  • Jacob Santana

  • Drew Thibault

  • Alejandro Pando

  • Nemanja Novakovic

  • Nehal S. Parikh

  • Morana Vojnic

  • Jonathan H. Sherman

  • May 16, 2026

Share

Original Source(s)

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?

  • by Yaxel Levin-Carrion, Jayant Bhasin, Kevin Titkov, Sraavya Anne, Arman Sawhney, Caryn J. Ha, Ibraheem Sharaf, Marvens Jean, Jacob Santana, Drew Thibault, Alejandro Pando, Nemanja Novakovic, Nehal S. Parikh, Morana Vojnic, Jonathan H. Sherman

  • May 16, 2026

Related Content

Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis

Predictors of Delayed and Omitted Postoperative Radiotherapy After Laryngectomy for pT4 Laryngeal Cancer

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC